Safety and Immunogenicity of a Recombinant Adenovirus Type-5 Vector-Based Ebola Vaccine in Healthy Adults in Sierra Leone: A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
The Lancet - United Kingdom
doi 10.1016/s0140-6736(16)32617-4
Full Text
Open PDFAbstract
Available in full text
Categories
Date
February 1, 2017
Authors
Publisher
Elsevier BV